LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Seegene Signs Contract to Deliver Shipment of Four Million Allplex SARS-CoV-2/FluA/FluB/RSV Assay to Brazil

By LabMedica International staff writers
Posted on 24 Feb 2022
Print article
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)

Seegene, Inc. (Seoul, Korea) has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.

Since January 2022, Brazil has battled a 'twindemic,' a rapid surge in both Flu A and COVID-19 infections due to the rapid spread of the Omicron variant. More seriously, new daily cases of COVID-19 have recently exceeded 280,000 cases, which is the highest figure since the first outbreak of the pandemic. While the country has been seeking to accelerate its quarantine efforts, there is a growing demand for COVID-19 tests as well. In response, Seegene will deliver a shipment of four million Allplex SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses including COVID-19, Flu A/B as well as RSV in a single test. This assay is expected to be the optimized solution in Brazil where they are experiencing a rapid surge in both COVID-19 and Flu A cases.

Meanwhile, in January this year, Seegene introduced Allplex SARS-CoV-2 Fast PCR Assay, a new assay optimized for mass testing. This assay can deliver PCR results in just 60 minutes enabling large-scale laboratories to easily scale up the testing volume up to three times without additional instruments. The launch of the new assay is a response to the rapid spread of the latest Omicron variant, globally. The new assay is expected to be the optimized choice for large-scale laboratories and help them immediately expand the testing capacity.

"Seegene is uniquely positioned to respond to the growing global need for COVID-19 and flu testing and we are fully prepared to supply global inventory to help countries around the world as they fight for everyday life to return," said Ho Yi, Chief Sales and Marketing Officer of Seegene.

Related Links:
Seegene, Inc.

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.